How to buy Savara stock | $1.45

Savara Inc is a biotechnology business based in the US. Savara shares (SVRA) are listed on the NASDAQ and all prices are listed in US Dollars. Savara employs 36 staff and has a trailing 12-month revenue of around USD$256,000.

How to buy shares in Savara

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Savara. Find the stock by name or ticker symbol: SVRA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Savara reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.45, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Savara, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Savara. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Savara share price

Use our graph to track the performance of SVRA stocks over time.

Savara shares at a glance

• Key figures

Information last updated 2020-12-01.

Latest market close	USD$1.45
52-week range	USD$0.995 - USD$4.55
50-day moving average	USD$1.1529
200-day moving average	USD$1.7384
Wall St. target price	USD$3.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.577

Buy Savara shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Savara stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Savara Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Savara price performance over time

Historical closes compared with the close of $1.45 from 2020-12-09

1 week (2021-01-08)	N/A
1 month (2020-12-15)	N/A
3 months (2020-10-15)	N/A
6 months (2020-07-15)	N/A

1 year (2020-01-15)	N/A
2 years (2019-01-15)	N/A
3 years (2018-01-15)	N/A
5 years (2016-01-15)	N/A

Savara financials

Revenue TTM	USD$256,000
Gross profit TTM	USD$0
Return on assets TTM	-22.44%
Return on equity TTM	-73.7%
Profit margin	0%
Book value	$1.415
Market capitalisation	USD$71.7 million

TTM: trailing 12 months

Shorting Savara shares

There are currently 945,160 Savara shares held short by investors – that's known as Savara's "short interest". This figure is 3.8% down from 982,974 last month.

There are a few different ways that this level of interest in shorting Savara shares can be evaluated.

Savara's "short interest ratio" (SIR)

Savara's "short interest ratio" (SIR) is the quantity of Savara shares currently shorted divided by the average quantity of Savara shares traded daily (recently around 144963.19018405). Savara's SIR currently stands at 6.52. In other words for every 100,000 Savara shares traded daily on the market, roughly 6520 shares are currently held short.

However Savara's short interest can also be evaluated against the total number of Savara shares, or, against the total number of tradable Savara shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Savara's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Savara shares in existence, roughly 20 shares are currently held short) or 0.0158% of the tradable shares (for every 100,000 tradable Savara shares, roughly 16 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Savara.

Find out more about how you can short Savara stock.

Savara share dividends

We're not expecting Savara to pay a dividend over the next 12 months.

Have Savara's shares ever split?

Savara's shares were split on 28 April 2017. This wouldn't directly have changed the overall worth of your Savara shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Savara shares which in turn could have impacted Savara's share price.

Savara share price volatility

Over the last 12 months, Savara's shares have ranged in value from as little as $0.995 up to $4.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Savara's is 1.0701. This would suggest that Savara's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Savara overview

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.

Frequently asked questions

• What percentage of Savara is owned by insiders or institutions?

  Currently 16.444% of Savara shares are held by insiders and 41.5% by institutions.

• How many people work for Savara?

  Latest data suggests 36 work at Savara.

• When does the fiscal year end for Savara?

  Savara's fiscal year ends in December.

• Where is Savara based?

  Savara's address is: Building III, Austin, TX, United States, 78746

• What is Savara's ISIN number?

  Savara's international securities identification number is: US8051111016

• What is Savara's CUSIP number?

  Savara's Committee on Uniform Securities Identification Procedures number is: 00764X103